ArchiMed nets 4x return on Fytexia exit

The GP bought Fytexia in 2016 via its small-cap MED I fund. It had around EUR 15m revenues in 2021.

MED I has returned four and a half times invested capital to limited partners to date, ArchiMed said in a statement; its total return – including four realised and five remaining investments – is seven times invested capital. 

The buyer, Associated British Foods, is a diversified food, ingredients and retail group in the FTSE 100. 

ArchiMed said that Fytexia's sales growth has risen from single digits to close to 30% for the past four years and that profits have risen fourfold. 

The GP just launched its second mid-cap fund, Med Platform II. 

ArchiMed said that Fytexia's strengths are in botanic and insect-based polyphenols, a type of antioxidant. In 2021, the company bolted on Italy-based B Natural, which boosted turnover by 40%. 

B Natural is one of Europe's largest companies in the commercialisation of propolis (a bee-generated compound used for hive construction), which contains the antioxidants. 

Unrealised assets in the Med I fund include orthopaedics implant provider Medistream, neuro systems monitoring company Micromed, and Vita Health Group (formerly known as RehabWorks).

Company
Fytexia offers nutritional ingredients developed through science-based research to reduce risk factors for non-communicable diseases. The company's activities range from the development of active compounds to the creation of clinically tested ingredients. 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• France
• Deals
• Consumer
• Archimed